摘要
2024年度肺动脉高压研究领域取得了许多令人瞩目的研究进展。在机制研究方面,学界对于血管重塑、代谢重编程、免疫微环境失调等多个病理生理环节取得了新的认识;在临床研究方面,新型靶向药物的研发与应用、无创神经调控技术的创新突破,以及基于生物标志物的个体化联合治疗策略的优化,均实现了多项革命性突破。本文对2024年度肺动脉高压的研究进展进行系统性回顾总结,以便研究者在此基础之上进行深入的研究探索与临床应用。
Significant advancements were made in the field of pulmonary hypertension(PH)research in 2024.In terms of mechanism studies,new insights were gained in various pathological and physiological processes,including vascular remodeling,metabolic reprogramming,and immune microenvironment dysregulation in PH.In clinical research,several revolutionary breakthroughs were achieved in novel targeted therapies,non-invasive neuroregulation techniques,and biomarker-based individualized combination treatments.This paper provided a systematic review of the research progress in pulmonary hypertension in 2024,aiming to facilitating further investigation and clinical application by researchers.
作者
赖家璇
陈豫钦
王健
Lai Jiaxuan;Chen Yuqin;Wang Jian(National Center for Respiratory Medicine,National Key Laboratory of Respiratory Diseases,Guangdong Key Laboratory of Vascular Diseases,National Clinical Research Center for Respiratory Diseases,Guangzhou Institute of Respiratory Health,Department of Respiratory and Critical Care Medicine,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China)
出处
《国际呼吸杂志》
2025年第6期465-470,共6页
International Journal of Respiration
基金
国家自然科学基金(82241012)。
关键词
高血压
肺性
发病机制
治疗
Hypertension,pulmonary
Pathogenesis
Treatment
作者简介
通信作者:王健,Email:jianwang@gzhmu.edu.cn。
